These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38433043)

  • 1. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
    Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e181-e190. PubMed ID: 38433043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: a retrospective claims analysis (2015-2020).
    Jun MP; Mutebi A; Chhibber A; Liang C; Keshishian A; Wang A; Rivas Navarro F; Kalsekar A; He J; Wang T
    J Med Econ; 2024; 27(1):1157-1167. PubMed ID: 39254695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
    Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
    Future Oncol; 2024 Feb; 20(6):317-328. PubMed ID: 38050764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Cazelles C; Belhadj K; Vellemans H; Camus V; Poullot E; Gaulard P; Veresezan L; Itti E; Becker S; Carvalho M; Dupuis J; Le Bras F; Lemonnier F; Roulin L; El Gnaoui T; Jardin F; Mounier N; Tilly H; Haioun C
    Leuk Lymphoma; 2021 Sep; 62(9):2161-2168. PubMed ID: 33764240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.
    Shen QD; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Li JY; Xu W
    Lancet Haematol; 2018 Jun; 5(6):e261-e269. PubMed ID: 29752199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
    Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
    Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
    Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
    Ren J; Asche CV; Shou Y; Galaznik A
    J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.
    Kurte MS; Siefen AC; Jakobs F; Poos T; von Tresckow J; von Tresckow B; Reinhardt HC; Kron F
    Eur J Haematol; 2024 Sep; 113(3):371-383. PubMed ID: 38853698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma.
    Gatwood J; Masaquel A; Fox D; Sheinson D; James C; Li J; Hossain F; Ross R
    J Med Econ; 2024; 27(1):738-745. PubMed ID: 38686393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
    Tsutsué S; Tobinai K; Yi J; Crawford B
    PLoS One; 2020; 15(8):e0237509. PubMed ID: 32810157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
    Rey-Búa B; Grande C; Sánchez Blanco JJ; Abrisqueta P; Gutiérrez A; Ramírez Páyer Á; Giné E; Zeberio Etxetxipia I; Terol MJ; de la Cruz Vicente F; Andreu R; Ramirez MJ; de la Fuente A; Viguria MC; Peñarrubia MJ; Jiménez-Ubieto A; Montes-Moreno S; López-Guillermo A; Caballero MD; Martín García-Sancho A
    Clin Cancer Res; 2024 Sep; 30(17):3704-3714. PubMed ID: 38900037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
    Corazzelli G; Capobianco G; Arcamone M; Ballerini PF; Iannitto E; Russo F; Frigeri F; Becchimanzi C; Marcacci G; De Chiara A; Pinto A
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):907-16. PubMed ID: 19219604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective.
    Moertl B; Dreyling M; Schmidt C; Hoster E; Schoel W; Bergwelt-Baildon MV; Berger K
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):474-482. PubMed ID: 35033478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
    Scheubeck G; Hoffmann M; Jurinovic V; Fischer L; Unterhalt M; Schmidt C; Böck HP; Dührsen U; Kaesberger J; Kremers S; Lindemann HW; Mantovani L; Hiddemann W; Hoster E; Dreyling M;
    Ann Hematol; 2024 Jul; 103(7):2373-2380. PubMed ID: 38459156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The care pathway of patients with diffuse large B-cell lymphoma described through Italian administrative healthcare data.].
    Dondi L; Ronconi G; Dondi L; Calabria S; Dell'Anno I; Piccinni C; Addesi A; Esposito I; Martini N
    Recenti Prog Med; 2024 Sep; 115(9):404-414. PubMed ID: 39269355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world.
    Ionescu-Ittu R; Shang A; Velde NV; Guerin A; Lin Y; Shi L; Shi S; Qayum N
    J Comp Eff Res; 2019 Oct; 8(13):1067-1075. PubMed ID: 31452397
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
    Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
    Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.